Combined with the results of this study, we believe that for most Chinese patients with HER2-positive advanced breast cancer and who underwent failed first-line treatments with trastuzumab, pyrrotinib plus chemotherapy is most likely the new ideal choice. Here, ERBB2 is linked to breast cancer.